Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

SEARCH was a large UK, randomised controlled trial of more intensive cholesterol-lowering with simvastatin 80mg daily versus a standard dose of simvastatin 20mg daily and of homocysteine-lowering with folic acid and vitamin B12 versus matching placebo. Between 1998 and 2001, 12,064 patients who had survived a heart attack were randomised in 88 hospital-based clinics around the UK. These patients were followed up for an average of about 7 years in the study clinics while they continued on their randomised treatment and follow-up is on-going for mortality and cancer via centralised electronic health records. 

SEARCH has shown that:

  • The additional reduction in LDL-cholesterol with allocation to simvastatin 80mg daily versus 20mg daily reduced LDL-cholesterol by 0.35 mmol/L and major vascular events (MVEs i.e. heart attacks, strokes or coronary or non-coronary revascularisation) by 6% (95% CI 12% to +1%). This reduction was in line with expectations and contributed to the CTT meta-analysis showing that more intensive LDL-cholesterol lowering produces additional benefits.
  • Supplementation with folic acid plus vitamin B12 significantly reduced homocysteine levels  and is safe, but does not reduce the risk of major vascular events or cancer
  • Simvastatin 80mg daily was associated with an increased risk of myopathy (muscle symptoms with raised blood creatine kinase) with 53 vs 2 cases respectively among those allocated 80mg vs 20mg simvastatin daily  
  • In a nested genetic case-control a genetic marker in the SLCO1B1 gene was shown to increase the risk of statin-induced myopathy

The SEARCH database continues to provide valuable information on other risk factors for myopathy. Data from SEARCH contributes to the CTT meta-analyses and the B Vitamin Treatment Trialists’ Collaboration (BVTTC) analyses. On-going investigations include looking at the long-term effects (over 10 years) of homocysteine-lowering on vascular and non-vascular deaths and cancers using data from electronic health records

The SEARCH trial was funded by Merck who also provided the packaged simvastatin and the packaged folic acid plus vitamin B12 combination tablet and matching placebos. The long-term follow-up is funded by core grants to CTSU from the Medical Research Council, British Heart Foundation and Cancer Research UK.

SEARCH: serious adverse events by MedRA classification

Our team

  • Jane Armitage
    Jane Armitage

    Professor of Clinical Trials and Epidemiology, and Honorary Consultant in Public Health Medicine

  • Louise Bowman
    Louise Bowman

    Professor of Medicine & Clinical Trials, and Honorary Consultant Physician (Lipidology)

  • Richard Bulbulia
    Richard Bulbulia

    Research Fellow, Clinical Trial Service Unit, University of Oxford

  • Robert Clarke
    Robert Clarke

    Emeritus Professor of Epidemiology and Public Health Medicine

  • Rory Collins
    Rory Collins

    Head of Nuffield Department of Population Health and BHF Professor of Medicine and Epidemiology

  • Richard Haynes
    Richard Haynes

    Professor of Renal Medicine and Clinical Trials


Unrestricted grant from Merck, Sharp and Dohne (see Unit's funding policy here)

Selected publications


ReSEARCH issue 1

262 KB, PDF document

ReSEARCH issue 2

992 KB, PDF document

ReSEARCH issue 3

800 KB, PDF document

ReSEARCH issue 4

300 KB, PDF document

ReSEARCH issue 5

1 MB, PDF document

Related research themes